C-reactive protein was introduced in this study as elevated levels in serum have been associated with shortened survival in metastatic melanoma patients and resistance to interleukin-2 therapy (Tartour et al, 1994; Mouawad et al, 1996; Tartour et al, 1996). This evidence concerns the gene IL2 and metastatic melanoma.